Shareholder Votes

TMC the metals Co Inc. shareholders approved The approval, on a non-binding advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Company's Proxy Statement (the “say-on-pay” vote). at the 2026-05-28 meeting.

“The approval, on a non-binding advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Company's Proxy Statement (the “say-on-pay” vote). Votes For Votes Against Votes Abstained 209,030,109 3,179,431 1,166,507”

TMC the metals Co Inc. shareholders approved Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year. at the 2026-05-28 meeting.

“Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year. Votes For Votes Withheld 212,951,132 424,915”

TMC the metals Co Inc. shareholders approved Election of the following directors of the Company, to serve until the Company's 2027 annual meeting of shareholders. at the 2026-05-28 meeting.

“Election of the following directors of the Company, to serve until the Company's 2027 annual meeting of shareholders and until their respective successors have been elected and qualified.”

TMC the metals Co Inc. shareholders approved Set the number of directors at ten (10). at the 2026-05-28 meeting.

“Set the number of directors at ten (10). Votes For Votes Against Votes Abstained 211,906,799 862,720 606,528”

Tenaya Therapeutics, Inc. shareholders approved Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan at the 2026-05-27 meeting.

“The stockholders approved the amendment and restatement of the Company’s 2021 Equity Incentive Plan.”

Tenaya Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-05-27 meeting.

“The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Tenaya Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-05-27 meeting.

“Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”

OCTAVE SPECIALTY GROUP INC shareholders approved Approval of 2026 Incentive Compensation Plan at the 2026-05-28 meeting.

“The Company’s stockholders approved the Company's 2026 Incentive Compensation Plan, as disclosed in the Company’s 2026 Proxy Statement, with the following vote:”

OCTAVE SPECIALTY GROUP INC shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-28 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 with the following vote:”

OCTAVE SPECIALTY GROUP INC shareholders approved Advisory vote on executive compensation at the 2026-05-28 meeting.

“The Company’s stockholders approved, by advisory (non-binding) vote, the compensation of our named executive officers, as disclosed in the Company’s 2026 Proxy Statement, with the following vote:”

OCTAVE SPECIALTY GROUP INC shareholders approved Election of seven directors at the 2026-05-28 meeting.

“The Company’s stockholders elected the seven (7) director nominees named below to a term expiring at the 2027 annual meeting or until their successors are elected and qualified, with each receiving the following votes:”

Skye Bioscience, Inc. shareholders approved Proposal No. 4: The approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. at the 2026-05-26 meeting.

“Proposal No. 4 : The approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated: For Against Abstain Broker Non-Votes 12,696,055 909,925 100,318 9,823,126”

Skye Bioscience, Inc. shareholders approved Proposal No. 3: The approval of the Charter Amendment. at the 2026-05-26 meeting.

“Proposal No. 3 : The approval of the Charter Amendment. The Charter Amendment was approved by the votes indicated: For Against Abstain 20,594,286 2,875,605 59,533”

Skye Bioscience, Inc. shareholders approved Proposal No. 2: The ratification of the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-26 meeting.

“Proposal No. 2 : The ratification of the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified by the votes indicated: For Against Abstain 22,802,045 542,634 184,745”

Skye Bioscience, Inc. shareholders approved Proposal No. 1: Election of Directors at the 2026-05-26 meeting.

“Proposal No. 1: Election of Directors. The stockholders elected each of the six nominees named in the proxy statement for the 2026 Annual Meeting (the “Proxy Statement”) as members of the Board of Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders. The results were as follows: Broker Director For Withhold Non-Votes Paul Grayson 13,194,721 511,577 9,823,126 Deborah Charych 13,293,551 412,747 9,823,126 Punit Dhillon 13,466,198 240,100 9,823,126 Annalisa Jenkins 13,491,428 214,870 9,823,126 Karen Smith 13,036,640 669,658 9,823,126 Andrew J. Schwab 13,408,440 297,858 9,823,126”

Snail, Inc. shareholders approved Ratification of the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-27 meeting.

“Proposal 2– The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote:”

Snail, Inc. shareholders approved Election of eight nominees for director to the Company's Board of Directors at the 2026-05-27 meeting.

“Proposal 1 –The stockholders elected the following eight (8) nominees for director to the Company’s Board of Directors to hold office until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified, based on the following votes:”

DigitalBridge Group, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-28 meeting.

“Proposal 4: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The table below sets forth the voting results for this proposal: Votes For Votes Against Abstentions Broker Non-Votes 147,487,500 726,395 66,216 —”

DigitalBridge Group, Inc. shareholders approved Approval of the Amendment to the Omnibus Plan at the 2026-05-28 meeting.

“Proposal 3: Approval of the Amendment to the Omnibus Plan. The Company’s stockholders approved the Plan Amendment. The table below sets forth the voting results for this proposal: Votes For Votes Against Abstentions Broker Non-Votes 118,023,425 3,924,132 76,978 26,255,576”

DigitalBridge Group, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-28 meeting.

“Proposal 2: Advisory Vote on Executive Compensation The Company’s stockholders approved (on an advisory, non-binding basis) the compensation of the Company’s named executive officers as described in the Compensation Discussion and Analysis and executive compensation tables of the Proxy Statement. The table below sets forth the voting results for this proposal: Votes For Votes Against Abstentions Broker Non-Votes 73,139,847 48,477,618 407,069 26,255,576”

DigitalBridge Group, Inc. shareholders approved Election of Directors at the 2026-05-28 meeting.

“Proposal 1: Election of Directors The following persons were duly elected to the Company’s Board of Directors to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, by the following vote: Name Votes For Votes Against Abstentions Broker Non-Votes James Keith Brown 89,516,687 28,567,187 3,940,660 26,255,576 Nancy A. Curtin 116,268,367 1,814,308 3,941,859 26,255,576 Jeannie H. Diefenderfer 89,303,561 28,779,393 3,941,580 26,255,576 Marc C. Ganzi 117,377,943 708,869 3,937,722 26,255,576 Gregory J. McCray 82,635,632 35,446,208 3,942,694 26,255,576 Sháka Rasheed 117,305,244 758,403 3,960,887 26,255,576 Dale Anne Reiss 117,011,975 1,071,203 3,941,356 26,255,576 David M. Tolley 116,956,195 1,120,415 3,947,924 26,255,576 Jay Wintrob 117,143,660 933,392 3,947,482 26,255,576”

FONAR CORP shareholders approved Section 203 approval of the Merger (vote of 66 2/3% of outstanding voting power not owned by Parent Entities). at the 2026-05-28 meeting.

“Section 203 Approval 6,502,501 551,079 17,171”

FONAR CORP shareholders approved Disinterested stockholder approval of the Merger (non-affiliated vote). at the 2026-05-28 meeting.

“Disinterested Stockholder Approval 3,279,090 551,079 17,171”

FONAR CORP shareholders approved To adopt and approve the Agreement and Plan of Merger, dated December 23, 2025, by and among FONAR, LLC, FONAR Acquisition Sub, Inc., and the Company, pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. at the 2026-05-28 meeting.

“For Against Abstain Company Stockholder Approval 13,124,769 551,079 17,171”

Spyre Therapeutics, Inc. shareholders approved Approval of Amended and Restated 2016 Employee Stock Purchase Plan at the 2026-05-27 meeting.

“The Company’s stockholders approved the Company's AR ESPP.”

Spyre Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2026-05-27 meeting.

“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”

Spyre Therapeutics, Inc. shareholders approved Advisory vote on the compensation of named executive officers at the 2026-05-27 meeting.

“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.”

Spyre Therapeutics, Inc. shareholders approved Election of three Class I directors at the 2026-05-27 meeting.

“The Company’s stockholders elected three Class I directors, Mark McKenna, Cameron Turtle, and Laurie Stelzer, each to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.”

NOVANTA INC shareholders approved Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm to serve until the Company's next Annual Meeting of Shareholders in 2027 at the 2026-05-28 meeting.

“Item 3 — Appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm to serve until the Company's next Annual Meeting of Shareholders in 2027. Votes FOR Votes AGAINST Votes ABSTAINED 33,352,532 5,006 14,239”

NOVANTA INC shareholders approved Approval, on an advisory basis, of the Company's executive compensation at the 2026-05-28 meeting.

“Item 2 — Approval, on an advisory basis, of the Company’s executive compensation. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 31,065,978 695,736 13,010 1,597,053”

NOVANTA INC shareholders approved Election of nine directors for a term of office expiring on the date of the Company's next Annual Meeting of Shareholders in 2027 at the 2026-05-28 meeting.

“Item 1 — Election of directors for a term of office expiring on the date of the Company's next Annual Meeting of Shareholders in 2027, until their successor is elected or appointed, or until their earlier death, resignation, or removal. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Lonny J. Carpenter 31,049,533 725,191 1,597,053 Matthew T. Farrell 31,739,890 34,834 1,597,053 Matthijs Glastra 30,975,206 799,518 1,597,053 R. Matthew Johnson 31,237,177 537,547 1,597,053 Mary Katherine Ladone 31,064,627 710,097 1,597,053 Maxine L. Mauricio 31,079,323 695,401 1,597,053 Thomas N. Secor 31,321,519 453,205 1,597,053 Darlene J. S. Solomon, Ph.D. 31,199,580 575,144 1,597,053 Frank A. Wilson 31,721,169 53,555 1,597,053”

Neuronetics, Inc. shareholders approved Approval of Neuronetics, Inc. 2026 Equity Incentive Plan at the 2026-05-28 meeting.

“Proposal 4: The approval of the Neuronetics, Inc. 2026 Equity Incentive Plan was approved by the Company’s stockholders by the votes set forth in the table below: 23,802,955 votes FOR the proposal 16,651,661 votes AGAINST the proposal 833,908 votes ABSTAIN 14,661,594 votes Broker Non-Votes”

Neuronetics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-28 meeting.

“Proposal 3: The approval, on a non-binding, advisory basis, of the compensation of the individual who served as our principal executive officer during 2025 and our two other most highly compensated executive officers who were serving as executive officers as of December 31, 2025 was ratified by the Company’s stockholders by the votes set forth in the table below: 29,133,360 votes FOR the proposal 11,503,294 votes AGAINST the proposal 651,870 votes ABSTAIN 14,661,594 votes Broker Non-Votes”

Neuronetics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.

“Proposal 2: The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders by the votes set forth in the table below: 47,194,967 votes FOR the proposal 6,924,816 votes AGAINST the proposal 1,830,335 votes ABSTAIN”

Neuronetics, Inc. shareholders approved Election of directors at the 2026-05-28 meeting.

“Proposal 1: All of the nominees for director were elected to serve a one-year term until the 2027 Annual Meeting, or until their respective successors are elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Avinash N. Amin, M.D. 33,982,534 7,305,990 14,661,594 Robert A. Cascella 29,304,597 11,983,927 14,661,594 Sheryl L. Conley 29,304,311 11,984,213 14,661,594 Sasha S. Cucuz 28,512,554 12,775,970 14,661,594 Glenn P. Muir 29,281,048 12,007,476 14,661,594 Daniel L. Reuvers 34,472,656 6,815,868 14,661,594 Megan R. Rosengarten 28,794,454 12,494,070 14,661,594”

ALTA EQUIPMENT GROUP INC. shareholders approved Approval of first amendment to Company's 2020 Omnibus Incentive Plan at the 2026-05-29 meeting.

“Proposal 4 The Company’s stockholders voted on and approved the first amendment to the Company's 2020 Omnibus Incentive Plan based upon the following votes: For Against Abstain Broker Non-Votes 14,055,464 8,761,489 564,111 4,614,578”

ALTA EQUIPMENT GROUP INC. shareholders approved Non-binding advisory vote on compensation paid to named executive officers at the 2026-05-29 meeting.

“Proposal 3 The Company’s stockholders approved in a non-binding advisory vote the compensation paid to our named executive officers based upon the following votes: For Against Abstain Broker Non-Votes 22,808,254 569,464 3,346 4,614,578”

ALTA EQUIPMENT GROUP INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 at the 2026-05-29 meeting.

“Proposal 2 The Company’s stockholders voted upon and approved the ratification of the appointment of Deloitte & Touche LLP to serve as the Company’s independent registered public accounting firm for 2026 based upon the following votes: For Against Abstain Broker Non-Votes 27,615,942 378,905 795 —”

ALTA EQUIPMENT GROUP INC. shareholders approved Election of three Class II director nominees at the 2026-05-29 meeting.

“Proposal 1 The three Class II director nominees named in our proxy statement were elected, each for a two-year term as set forth in the Company’s proxy statement dated April 15, 2026.”

MONARCH CASINO & RESORT INC shareholders approved Advisory vote on executive compensation at the 2026-05-27 meeting.

“Proposal 2 – Stockholders approved, on a non-binding advisory basis, the executive compensation as disclosed in the 2026 proxy statement of the Company's named executive officers.”

MONARCH CASINO & RESORT INC shareholders approved Election of Directors at the 2026-05-27 meeting.

“Proposal 1 – Stockholders elected John Farahi, Craig F. Sullivan and Paul Andrews, each nominated by the board of directors, to serve until the 2028 annual meeting of stockholders and until his successor is elected and qualified, or until such director's earlier death, resignation or removal. Stockholders elected Hope S. Taitz, nominated by the board of directors, to serve until the 2027 annual meeting of stockholders and until her successor is elected and qualified, or until such director's earlier death, resignation or removal.”

Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of compensation of named executive officers at the 2026-05-29 meeting.

“Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.”

Kiniksa Pharmaceuticals International, plc shareholders approved Approve UK Statutory Directors’ Remuneration Policy at the 2026-05-29 meeting.

“Proposal 7 - To approve the Company’s UK Statutory Directors’ Remuneration Policy.”

Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of UK Statutory Directors’ Annual Remuneration Report for period ended December 31, 2025 at the 2026-05-29 meeting.

“Proposal 6 - To approve, on an advisory non-binding basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025.”

Kiniksa Pharmaceuticals International, plc shareholders approved Receive UK statutory annual account and report for period ended December 31, 2025 at the 2026-05-29 meeting.

“Proposal 5 - To receive the Company’s UK statutory annual account and report for the period ended December 31, 2025.”

Kiniksa Pharmaceuticals International, plc shareholders approved Authorize board of directors, through audit committee, to determine PwC’s remuneration as UK statutory auditors at the 2026-05-29 meeting.

“Proposal 4 - To authorize the Company’s board of directors, through its audit committee, to determine PwC’s remuneration in its capacity as the Company’s UK statutory auditors until the close of its next Annual Meeting of Shareholders.”

Kiniksa Pharmaceuticals International, plc shareholders approved Ratify appointment of PwC as US independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-29 meeting.

“Proposal 3 - To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as UK statutory auditors at the 2026-05-29 meeting.

“Proposal 2 - To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of the Company’s next Annual Meeting.”

Kiniksa Pharmaceuticals International, plc shareholders approved Re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors at the 2026-05-29 meeting.

“Proposal 1 - The re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve on the Board of Directors until the 2029 Annual Meeting of Shareholders”

HEALTHSTREAM INC shareholders approved Non-binding advisory resolution on executive compensation at the 2026-05-28 meeting.

“FOR AGAINST ABSTAIN BROKER NON VOTES 23,852,346 1,019,058 3,001 2,654,245”